Daniel Erskine

2.6k total citations
47 papers, 1.4k citations indexed

About

Daniel Erskine is a scholar working on Neurology, Physiology and Neurology. According to data from OpenAlex, Daniel Erskine has authored 47 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Neurology, 20 papers in Physiology and 12 papers in Neurology. Recurrent topics in Daniel Erskine's work include Parkinson's Disease Mechanisms and Treatments (25 papers), Alzheimer's disease research and treatments (17 papers) and Neurological disorders and treatments (10 papers). Daniel Erskine is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (25 papers), Alzheimer's disease research and treatments (17 papers) and Neurological disorders and treatments (10 papers). Daniel Erskine collaborates with scholars based in United Kingdom, United States and Qatar. Daniel Erskine's co-authors include Johannes Attems, Ian G. McKeith, Alan Thomas, Lauren Walker, John‐Paul Taylor, Kirsty E. McAleese, Christopher M. Morris, David J. Koss, Omar M. A. El‐Agnaf and Nour K. Majbour and has published in prestigious journals such as Brain, Neurology and Scientific Reports.

In The Last Decade

Daniel Erskine

43 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Erskine United Kingdom 20 758 604 338 312 276 47 1.4k
Yulia Surova Sweden 17 1.2k 1.6× 555 0.9× 445 1.3× 257 0.8× 254 0.9× 20 1.7k
Nadia Magdalinou United Kingdom 17 750 1.0× 840 1.4× 490 1.4× 404 1.3× 388 1.4× 22 1.7k
Omi Katsuse Japan 27 1.1k 1.5× 949 1.6× 428 1.3× 338 1.1× 291 1.1× 55 1.9k
Kazutomi Kanemaru Japan 18 637 0.8× 506 0.8× 217 0.6× 278 0.9× 198 0.7× 55 1.3k
Oriol Dols‐Icardo Spain 16 564 0.7× 700 1.2× 335 1.0× 323 1.0× 212 0.8× 40 1.2k
Steffen Halbgebauer Germany 19 598 0.8× 561 0.9× 308 0.9× 443 1.4× 294 1.1× 46 1.3k
Allan K. Hansen Denmark 19 738 1.0× 433 0.7× 227 0.7× 153 0.5× 169 0.6× 36 1.4k
Naomi Kouri United States 16 686 0.9× 671 1.1× 326 1.0× 262 0.8× 191 0.7× 31 1.2k
David J. Koss United Kingdom 18 368 0.5× 652 1.1× 227 0.7× 307 1.0× 148 0.5× 37 1.2k
W Richard Bevan‐Jones United Kingdom 22 442 0.6× 787 1.3× 483 1.4× 272 0.9× 401 1.5× 39 1.5k

Countries citing papers authored by Daniel Erskine

Since Specialization
Citations

This map shows the geographic impact of Daniel Erskine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Erskine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Erskine more than expected).

Fields of papers citing papers by Daniel Erskine

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Erskine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Erskine. The network helps show where Daniel Erskine may publish in the future.

Co-authorship network of co-authors of Daniel Erskine

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Erskine. A scholar is included among the top collaborators of Daniel Erskine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Erskine. Daniel Erskine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Erskine, Daniel, et al.. (2025). Sphingolipidoses: expanding the spectrum of α-synucleinopathies. Journal of Neural Transmission. 1 indexed citations
2.
Koss, David J., L. Findlay, Paweł Palmowski, et al.. (2025). A reciprocal relationship between markers of genomic DNA damage and alpha-synuclein pathology in dementia with Lewy bodies. Molecular Neurodegeneration. 20(1). 34–34. 2 indexed citations
3.
Lax, Nichola Z., Yi Shiau Ng, Robert W. Taylor, et al.. (2025). Delineating the mechanisms of cerebellar degeneration in paediatric and adult primary mitochondrial disease. Acta Neuropathologica. 149(1). 53–53.
4.
Hamilton, Calum A., Fiona E. Matthews, Johannes Attems, et al.. (2024). Associations between multimorbidity and neuropathology in dementia: consideration of functional cognitive disorders, psychiatric illness and dementia mimics. The British Journal of Psychiatry. 224(6). 237–244.
5.
Kataura, Tetsushi, Lucia Sedlackova, Niall Wilson, et al.. (2024). Targeting the autophagy-NAD axis protects against cell death in Niemann-Pick type C1 disease models. Cell Death and Disease. 15(5). 382–382. 8 indexed citations
6.
Espay, Alberto J., Andrew Lees, Francisco Cardoso, et al.. (2024). The α-synuclein seed amplification assay: Interpreting a test of Parkinson's pathology. Parkinsonism & Related Disorders. 131. 107256–107256. 6 indexed citations
7.
Gorman, Gráinne S., et al.. (2023). Neurological Phenotypes in Mouse Models of Mitochondrial Disease and Relevance to Human Neuropathology. International Journal of Molecular Sciences. 24(11). 9698–9698. 2 indexed citations
8.
Chen, Chun, David McDonald, Alasdair Blain, et al.. (2023). Parkinson’s disease neurons exhibit alterations in mitochondrial quality control proteins. npj Parkinson s Disease. 9(1). 120–120. 21 indexed citations
9.
Chen, Chun, et al.. (2023). Astrocytic pathology in Alpers’ syndrome. Acta Neuropathologica Communications. 11(1). 86–86. 7 indexed citations
10.
Erskine, Daniel, et al.. (2022). Delineating selective vulnerability of inhibitory interneurons in Alpers' syndrome. Neuropathology and Applied Neurobiology. 48(6). e12833–e12833. 11 indexed citations
11.
Hmila, Issam, Nishant N. Vaikath, Nour K. Majbour, et al.. (2022). Novel engineered nanobodies specific for N‐terminal region of alpha‐synuclein recognize Lewy‐body pathology and inhibit in‐vitro seeded aggregation and toxicity. FEBS Journal. 289(15). 4657–4673. 17 indexed citations
12.
Koss, David J., et al.. (2022). Nuclear alpha-synuclein is present in the human brain and is modified in dementia with Lewy bodies. Acta Neuropathologica Communications. 10(1). 98–98. 43 indexed citations
13.
Erskine, Daniel & Johannes Attems. (2021). Insights into Lewy body disease from rare neurometabolic disorders. Journal of Neural Transmission. 128(10). 1567–1575. 7 indexed citations
14.
Erskine, Daniel, David J. Koss, Viktor I. Korolchuk, et al.. (2021). Lipids, lysosomes and mitochondria: insights into Lewy body formation from rare monogenic disorders. Acta Neuropathologica. 141(4). 511–526. 38 indexed citations
15.
Hamilton, Calum A., Fiona E. Matthews, Daniel Erskine, Johannes Attems, & Alan Thomas. (2021). Neurodegenerative brain changes are associated with area deprivation in the United Kingdom: findings from the Brains for Dementia Research study. Acta Neuropathologica Communications. 9(1). 198–198. 9 indexed citations
16.
Gupta, Vijay, Issam Hmila, Nishant N. Vaikath, et al.. (2020). Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity. Scientific Reports. 10(1). 8137–8137. 15 indexed citations
17.
Reeve, Amy K., Nichola Z. Lax, Alasdair Blain, et al.. (2020). Complex I reductions in the nucleus basalis of Meynert in Lewy body dementia: the role of Lewy bodies. Acta Neuropathologica Communications. 8(1). 103–103. 16 indexed citations
18.
Erskine, Daniel, John‐Paul Taylor, Geor Bakker, et al.. (2019). Cholinergic muscarinic M1 and M4 receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders. Drug Discovery Today. 24(12). 2307–2314. 38 indexed citations
19.
Outeiro, Tiago F., David J. Koss, Daniel Erskine, et al.. (2019). Dementia with Lewy bodies: an update and outlook. Molecular Neurodegeneration. 14(1). 5–5. 242 indexed citations
20.
McAleese, Kirsty E., Lauren Walker, Sophie Graham, et al.. (2017). Parietal white matter lesions in Alzheimer’s disease are associated with cortical neurodegenerative pathology, but not with small vessel disease. Acta Neuropathologica. 134(3). 459–473. 176 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yulia Surova Breakdown of academic impact, for papers by Nadia Magdalinou Breakdown of academic impact, for papers by Omi Katsuse Breakdown of academic impact, for papers by Kazutomi Kanemaru Breakdown of academic impact, for papers by Oriol Dols‐Icardo Breakdown of academic impact, for papers by Steffen Halbgebauer Breakdown of academic impact, for papers by Allan K. Hansen Breakdown of academic impact, for papers by Naomi Kouri Breakdown of academic impact, for papers by David J. Koss Breakdown of academic impact, for papers by W Richard Bevan‐Jones
Rankless by CCL
2026